|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Asghar U and Meyer T: Are there
opportunities for chemotherapy in the treatment of hepatocellular
cancer? J Hepatol. 56:686–695. 2012. View Article : Google Scholar
|
|
3
|
Sukowati CH, Rosso N, Crocè LS and
Tiribelli C: Hepatic cancer stem cells and drug resistance:
Relevance in targeted therapies for hepatocellular carcinoma. World
J Hepatol. 2:114–126. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wong H and Schotz MC: The lipase gene
family. J Lipid Res. 43:993–999. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Santamarina-Fojo S, González-Navarro H,
Freeman L, Wagner E and Nong Z: Hepatic lipase, lipoprotein
metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol.
24:1750–1754. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nomura DK, Long JZ, Niessen S, Hoover HS,
Ng SW and Cravatt BF: Monoacylglycerol lipase regulates a fatty
acid network that promotes cancer pathogenesis. Cell. 140:49–61.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ding Q, Chang CJ, Xie X, Xia W, Yang JY,
Wang SC, Wang Y, Xia J, Chen L, Cai C, et al: APOBEC3G promotes
liver metastasis in an orthotopic mouse model of colorectal cancer
and predicts human hepatic metastasis. J Clin Invest.
121:4526–4536. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Galluzzi L, Goubar A, Olaussen KA, Vitale
I, Senovilla L, Michels J, Robin A, Dorvault N, Besse B, Validire
P, et al: Prognostic value of LIPC in non-small cell lung
carcinoma. Cell Cycle. 12:647–654. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma S, Lee TK, Zheng BJ, Chan KW and Guan
XY: CD133+ HCC cancer stem cells confer chemoresistance
by preferential expression of the Akt/PKB survival pathway.
Oncogene. 27:1749–1758. 2008. View Article : Google Scholar
|
|
10
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar
|
|
11
|
Livak and Schmittgen: Analysis of relative
gene expression data using real-time quantitative PCR and the
2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
|
|
12
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar
|
|
13
|
Stein W, Bohner J and Bahlinger M: Macro
lipase - a new member of the family of immunoglobulin-linked
enzymes. J Clin Chem Clin Biochem. 25:837–843. 1987.PubMed/NCBI
|
|
14
|
Muñoz-Perez M, Sarrion-Pelous D,
Jimenez-Jimenez J, Martinez-Montiel P and Gallego-Valdes M: Chronic
increased serum lipase in a patient with suspected pancreatic
adenocarcinoma. Clin Chem. 43:191–193. 1997.PubMed/NCBI
|
|
15
|
Diani G, Poma G, Novazzi F, Zanirato S,
Porta C, Moroni M, Melzi d’ Eril GV and Moratti R: Increased serum
lipase with associated normoamylasemia in cancer patients. Clin
Chem. 44:1043–1045. 1998.PubMed/NCBI
|
|
16
|
Singh SK, Clarke ID, Terasaki M, Bonn VE,
Hawkins C, Squire J and Dirks PB: Identification of a cancer stem
cell in human brain tumors. Cancer Res. 63:5821–5828.
2003.PubMed/NCBI
|
|
17
|
Fang D, Nguyen TK, Leishear K, Finko R,
Kulp AN, Hotz S, Van Belle PA, Xu X, Elder DE and Herlyn M: A
tumorigenic subpopulation with stem cell properties in melanomas.
Cancer Res. 65:9328–9337. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Collins AT, Berry PA, Hyde C, Stower MJ
and Maitland NJ: Prospective identification of tumorigenic prostate
cancer stem cells. Cancer Res. 65:10946–10951. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miki J, Furusato B, Li H, Gu Y, Takahashi
H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S and Rhim JS:
Identification of putative stem cell markers, CD133 and CXCR4, in
hTERT-immortalized primary nonmalignant and malignant tumor-derived
human prostate epithelial cell lines and in prostate cancer
specimens. Cancer Res. 67:3153–3161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
O’Brien CA, Pollett A, Gallinger S and
Dick JE: A human colon cancer cell capable of initiating tumour
growth in immunodeficient mice. Nature. 445:106–110. 2007.
View Article : Google Scholar
|
|
21
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar
|
|
22
|
Suetsugu A, Nagaki M, Aoki H, Motohashi T,
Kunisada T and Moriwaki H: Characterization of CD133+
hepatocellular carcinoma cells as cancer stem/progenitor cells.
Biochem Biophys Res Commun. 351:820–824. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yin S, Li J, Hu C, Chen X, Yao M, Yan M,
Jiang G, Ge C, Xie H, Wan D, et al: CD133 positive hepatocellular
carcinoma cells possess high capacity for tumorigenicity. Int J
Cancer. 120:1444–1450. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bao S, Wu Q, Sathornsumetee S, Hao Y, Li
Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD and Rich JN: Stem
cell-like glioma cells promote tumor angiogenesis through vascular
endothelial growth factor. Cancer Res. 66:7843–7848. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shmelkov SV, Butler JM, Hooper AT, Hormigo
A, Kushner J, Milde T, St Clair R, Baljevic M, White I, Jin DK, et
al: CD133 expression is not restricted to stem cells, and both
CD133+ and CD133− metastatic colon cancer
cells initiate tumors. J Clin Invest. 118:2111–2120.
2008.PubMed/NCBI
|
|
26
|
Meng X, Li M, Wang X, Wang Y and Ma D:
Both CD133+ and CD133− subpopulations of A549
and H446 cells contain cancer-initiating cells. Cancer Sci.
100:1040–1046. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jaksch M, Múnera J, Bajpai R, Terskikh A
and Oshima RG: Cell cycle-dependent variation of a CD133 epitope in
human embryonic stem cell, colon cancer, and melanoma cell lines.
Cancer Res. 68:7882–7886. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang JD, Nakamura I and Roberts LR: The
tumor microenvironment in hepatocellular carcinoma: Current status
and therapeutic targets. Semin Cancer Biol. 21:35–43. 2011.
View Article : Google Scholar :
|
|
29
|
Cheung ST, Leung KL, Ip YC, Chen X, Fong
DY, Ng IO, Fan ST and So S: Claudin-10 expression level is
associated with recurrence of primary hepatocellular carcinoma.
Clin Cancer Res. 11:551–556. 2005.PubMed/NCBI
|
|
30
|
Ip YC, Cheung ST, Lee YT, Ho JC and Fan
ST: Inhibition of hepatocellular carcinoma invasion by suppression
of claudin-10 in HLE cells. Mol Cancer Ther. 6:2858–2867. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Suh Y, Yoon CH, Kim RK, Lim EJ, Oh YS,
Hwang SG, An S, Yoon G, Gye MC, Yi JM, et al: Claudin-1 induces
epithelial-mesenchymal transition through activation of the
c-Abl-ERK signaling pathway in human liver cells. Oncogene.
32:4873–4882. 2013. View Article : Google Scholar
|
